论文信息 - KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. - 字舞流文

KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.

Jeffrey S. Morris | Jing Wang | J. Minna | J. Roth | S. Swisher | J. Heymach | F. Meric-Bernstam | Y. Xi | Jianhua Zhang | C. Ren | D. Gibbons | M. Ha | B. Fang | Li Wang | Shuhong Wu | Q. Meng | Xiaoshan Zhang | Huiqin Chen | A. Pataer | Ran Zhang | J. Heymach